Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PACB vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MXCT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–2 Matrix Metrics)

MXCT Overall Winner 6-Pillar Tally: PACB 1 – 4 MXCT (1 Tie) Matrix Metrics: PACB 2 – 5 MXCT

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 50.1/100 (HOLD) at $1.63 (N/M Forward P/E, -333.0% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -333.0% operating margin) and revenue trajectory (+48.7% vs. +5.5% YoY).
  • Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PACB vs MXCT
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.63
-7.39% 1D
Market Cap $549.5M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.25β · 104% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 55.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.4 · SMA20: $2.23 · SMA50: $2.05
MXCT NASDAQ Head-to-Head Winner
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (PACB 1 – 4 MXCT)

Columns: Metric · PACB · MXCT
1. Valuation Multiples MXCT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x 3.9x
2. Growth & Scale PACB
Revenue Growth (YoY) +5.5% +48.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $161M $34M
Market Cap $549.5M $132.2M
3. Profitability & Quality MXCT
Gross Margin 27.7% 81.0%
Operating Margin -333.0% -85.5%
Net Profit Margin -81.3% -81.4%
Return on Equity (ROE) -929.3% -16.9%
4. Balance Sheet & Cash Flow MXCT
Cash Generation (TTM) -$150M -$24M
Cash Flow Margin -93.2% -69.2%
Net Cash / Leverage $649M Net Debt $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 191.0% (97th %ile) N/A (N/A)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PACB (2) vs MXCT (5)
Institutional Metric PACB MXCT Criterion Row Edge
Market Capitalization
Scale
$549.5M $132.2M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+5.5% +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-333.0% -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
-81.3% -81.4% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-929.3% -16.9% Higher ROE MXCT
52-Week Range Position
Momentum
24% ($1–$3) 63% ($1–$2) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
2.25β · 104% Vol 1.19β · 96% Vol Lower Realized Risk MXCT
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
$161M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
27.7% 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($649M Net Debt) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +16.67 pp
PACB: -20.87% · MXCT: -4.2%
3M Horizon PACB +28.78 pp
PACB: +27.34% · MXCT: -1.44%
6M Horizon PACB +1.88 pp
PACB: +33.61% · MXCT: +31.73%
1Y Horizon PACB +12.02 pp
PACB: -7.39% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PACB Revenue MXCT Revenue PACB Op. Margin MXCT Op. Margin Margin Leader
FY2018 $80M N/A -128.4% N/A PACB
FY2019 $90M $10M -110.6% -93.7% MXCT
FY2020 $80M $20M -132.3% -71.6% MXCT
FY2021 $130M $20M -161.2% -84.3% MXCT
FY2022 $130M $30M -239.4% -95.2% MXCT
FY2023 $200M $20M -166.8% -247.7% PACB
FY2024 $150M $20M -308.0% -230.5% MXCT
FY2025 $160M $20M -346.2% -247.6% MXCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PACB BREAKDOWN
16d in phase · OBV DISTRIBUTION
Current IV 191.0%
IV Percentile 97th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $549.5M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PACB vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 50.1/100 (HOLD) at $1.63 (N/M Forward P/E, -333.0% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -333.0% operating margin) and revenue trajectory (+48.7% vs. +5.5% YoY). Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACB cumulative revenue shifted +100.0% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

MXCT screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-93.2% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.25β · 104% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.